Cargando…

Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?

COVID-19 has rapidly become a pandemic worldwide, causing extensive and long-term health issues. There is an urgent need to identify therapies that limit SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Unbalanced lung inflammation is a common feature in severe COVID-19 patients; t...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Changbo, Fuhler, Gwenny M., Pan, Yihang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199351/
https://www.ncbi.nlm.nih.gov/pubmed/34073529
http://dx.doi.org/10.3390/ijms22115672
_version_ 1783707356380528640
author Qu, Changbo
Fuhler, Gwenny M.
Pan, Yihang
author_facet Qu, Changbo
Fuhler, Gwenny M.
Pan, Yihang
author_sort Qu, Changbo
collection PubMed
description COVID-19 has rapidly become a pandemic worldwide, causing extensive and long-term health issues. There is an urgent need to identify therapies that limit SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Unbalanced lung inflammation is a common feature in severe COVID-19 patients; therefore, reducing lung inflammation can undoubtedly benefit the clinical manifestations. Histamine H1 receptor (H1 receptor) antagonists are widely prescribed medications to treat allergic diseases, while recently it has emerged that they show significant promise as anti-SARS-CoV-2 agents. Here, we briefly summarize the novel use of H1 receptor antagonists in combating SARS-CoV-2 infection. We also describe the potential antiviral mechanisms of H1 receptor antagonists on SARS-CoV-2. Finally, the opportunities and challenges of the use of H1 receptor antagonists in managing COVID-19 are discussed.
format Online
Article
Text
id pubmed-8199351
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81993512021-06-14 Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19? Qu, Changbo Fuhler, Gwenny M. Pan, Yihang Int J Mol Sci Review COVID-19 has rapidly become a pandemic worldwide, causing extensive and long-term health issues. There is an urgent need to identify therapies that limit SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Unbalanced lung inflammation is a common feature in severe COVID-19 patients; therefore, reducing lung inflammation can undoubtedly benefit the clinical manifestations. Histamine H1 receptor (H1 receptor) antagonists are widely prescribed medications to treat allergic diseases, while recently it has emerged that they show significant promise as anti-SARS-CoV-2 agents. Here, we briefly summarize the novel use of H1 receptor antagonists in combating SARS-CoV-2 infection. We also describe the potential antiviral mechanisms of H1 receptor antagonists on SARS-CoV-2. Finally, the opportunities and challenges of the use of H1 receptor antagonists in managing COVID-19 are discussed. MDPI 2021-05-26 /pmc/articles/PMC8199351/ /pubmed/34073529 http://dx.doi.org/10.3390/ijms22115672 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Qu, Changbo
Fuhler, Gwenny M.
Pan, Yihang
Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
title Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
title_full Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
title_fullStr Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
title_full_unstemmed Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
title_short Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
title_sort could histamine h1 receptor antagonists be used for treating covid-19?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199351/
https://www.ncbi.nlm.nih.gov/pubmed/34073529
http://dx.doi.org/10.3390/ijms22115672
work_keys_str_mv AT quchangbo couldhistamineh1receptorantagonistsbeusedfortreatingcovid19
AT fuhlergwennym couldhistamineh1receptorantagonistsbeusedfortreatingcovid19
AT panyihang couldhistamineh1receptorantagonistsbeusedfortreatingcovid19